← Back to Search

Oxytocin

Oxytocin Management for Induced Birth ((REDUCED-I) Trial)

N/A
Waitlist Available
Led By Stephen L Wood, MD, FRCSC
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years old or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 28 days of delivery
Awards & highlights

(REDUCED-I) Trial Summary

This trial is testing whether or not stopping oxytocin during labor will reduce the number of c-sections.

Who is the study for?
The REDUCED-I Pilot Trial is for first-time mothers who are at least 37 weeks pregnant with one baby in head-down position, undergoing labor induction with oxytocin. Women must be 18 or older. Those with multiple babies or known fetal anomalies cannot participate.Check my eligibility
What is being tested?
This trial tests whether stopping oxytocin after the active stage of labor begins (when dilation reaches at least 6 cm) can reduce the need for cesarean sections without increasing risks to mother and baby.See study design
What are the potential side effects?
Since this trial involves standard procedures already used during induced labor, side effects may include typical labor-related discomforts but aim to avoid complications like uterine hyperstimulation and fetal distress.

(REDUCED-I) Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

(REDUCED-I) Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and at delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of Uterine Hyperstimulation
Proportion of screened subjects who agree to enroll in the trial
Rate of Cesarean section in labor
Secondary outcome measures
Rate of blood transfusion
Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic cooling
Rate of neonatal asphyxia
+6 more
Other outcome measures
Duration of oxytocin discontinuation
Rate of reintroduction of oxytocin infusion

(REDUCED-I) Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention site (Foothills Medical Centre): Continuation of OxytocinExperimental Treatment1 Intervention
Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be >= 6 cm dilated.
Group II: Intervention site (Foothills Medical Centre): Discontinuation of oxytocinPlacebo Group1 Intervention
Participants in this arm will receive a blinded vial of saline solution once a patient is found to be >= 6 cm dilated.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
2021
N/A
~210

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
795 Previous Clinical Trials
874,374 Total Patients Enrolled
Stephen L Wood, MD, FRCSCPrincipal InvestigatorUniversity of Calgary

Media Library

Continuation or Discontinuation of Oxytocin (Oxytocin) Clinical Trial Eligibility Overview. Trial Name: NCT05037617 — N/A
Induced Birth Research Study Groups: Intervention site (Foothills Medical Centre): Continuation of Oxytocin, Intervention site (Foothills Medical Centre): Discontinuation of oxytocin
Induced Birth Clinical Trial 2023: Continuation or Discontinuation of Oxytocin Highlights & Side Effects. Trial Name: NCT05037617 — N/A
Continuation or Discontinuation of Oxytocin (Oxytocin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05037617 — N/A
~57 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top